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Abstract
Introduction Vascular hyporeactivity is an important problem
associated with sepsis. Although the mechanism involves
inflammatory pathway activation, specific therapeutic
approaches have not been defined. Glutamine (Gln) has been
shown to provide some anti-inflammatory effects and improve
outcomes in sepsis. Here, we tested the hypothesis that Gln
could reduce Escherichia coli lipopolysaccharide (LPS)-
induced vascular hyporeactivity and evaluated the role of heat-
shock protein 70 (HSP70) induction in this process.
Methods Twenty-four male Sprague-Dawley rats were divided
into control, LPS shock, and alanyl-Gln dipeptide+LPS shock
(Ala-Gln+LPS) groups. Six hours after administration of LPS,
phenylephrine (PE) (0.5 to approximately 2.5 μg/kg) was
applied intravenously to all groups, and the percentage increase
in mean arterial pressure (MAP) was detected in the respective
groups. The concentration-response curve of PE was obtained
in tension experiments, and the average values of PE maximum
efficacy (Emax) and median effective dose (EC50) were
calculated. The plasma concentrations of malondialdehyde
(MDA), tumor necrosis factor-alpha (TNF-α), and interleukin-6
(IL-6) were detected in all groups. The expressions of HSP70
from heart, liver, lung, and aorta were also assayed in all groups.
Results The maximal percentage increase in MAP induced by
PE was significantly reduced to 12.7% in the LPS shock group
(P < 0.05) and was restored to 15.6% in the Ala-Gln+LPS
group (P < 0.05), whereas the control group was 24.7%. The
average values of PE Emax and EC50 were significantly impaired
in the LPS shock group (P < 0.05) but partially restored in the
Ala-Gln+LPS group (P < 0.05). The expressions of HSP70 from
the heart, aorta, lung, and liver were much higher in the Ala-
Gln+LPS group than those in the LPS shock group (P < 0.05).
The plasma concentrations of TNF-α, IL-6, and MDA were much
lower in the Ala-Gln+LPS group than those in the LPS shock
group.
Conclusion Gln effectively improves vascular reactivity by
inducing the expression of HSP70, reducing inflammatory
cytokine release and peroxide biosynthesis in LPS shock rats.
These results suggest that Gln has a potentially beneficial
therapeutic effect for septic shock patients.
Introduction
Septic shock is a complex pathophysiological state, and
despite considerable therapeutic advances, it remains a major
therapeutic challenge with a high incidence of mortality [1].
Vascular hyporeactivity to catecholamine vasoconstrictors is a
characteristic feature of septic shock, plays a key role in this
pathological process, and results in arterial hypotension, mul-
tiple organ dysfunction, and death. The underlying mechanism
of impaired vasopressor responsiveness in septic shock is not
completely understood but likely involves the activation of
inflammatory pathways [2].
The therapeutic approaches for the treatment of vascular
hyporeactivity in septic shock have included using high-dose
vasoactive agents, nitric oxide synthases inhibitors [3], guan-
ylate cyclase inhibitor [4], low-dose corticosteroids [5], and
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antioxidant therapy [6]. These have been experimentally used
in clinical and animal studies, but their value in therapeutics is
not proven. Thus, the precise mechanisms of cardiovascular
dysfunction during sepsis warrant further study and the new
therapeutic approaches should be explored.
Heat-shock proteins (HSPs) are self-protective proteins that
maintain cell homeostasis against various forms of stress as an
adaptive response [7]. These proteins are induced by a wide
variety of stressors and have broad cytoprotective functions.
The 70-kDa family of HSP (HSP70), in particular, plays a vital
role in cellular protection and has been detected in various tis-
sues subject to stress [8,9]. Heat stress, gene transfer, and
some small-molecule agents have been reported to induce
HSP70 expression [10-12], but the potential clinical value of
these approaches has not been defined.
Glutamine (Gln), a non-essential amino acid, has been demon-
strated to attenuate pro-inflammatory cytokine release [13]
and lung metabolic dysfunction in animal models of endotoxin
shock through enhanced HSP expression [14]. No previous
studies have evaluated the impact of Gln administration on
sepsis-related vascular hyporeactivity. In this study, we exam-
ined the hypothesis that pretreatment of Gln could induce
HSP70 expression and improve vascular reactivity in a rele-
vant rat model of lipopolysaccharide (LPS)-induced sepsis.
Materials and methods
Animals
The study was approved by the Ethical Committee of Animal
Research at the College of Medicine, Southeast University,
Nanjing, China. Twenty-four healthy male Sprague-Dawley
rats weighing 250 to approximately 300 g were randomly
divided into three groups: a control group, which received an
intravenous infusion of 5 to 7 ml of lactated Ringer's solution
(LR) (n = 8); an LPS shock group, which received an intrave-
nous infusion of 5 to 7 ml of LR until one hour before intrave-
nous administration of LPS (Sigma-Aldrich, St. Louis, MO,
USA) 10 mg/kg (n = 8); and an alanyl-Gln dipeptide+LPS
shock (Ala-Gln+LPS) group, which received an intravenous
infusion of 5 to 7 ml of 4% Ala-Gln until one hour before intra-
venous administration of LPS (n = 8). All fluids were infused
by micropump at a rate of 5 to 7 ml/hour.
Glutamine administration
Gln was administered as 20% Ala-Gln (Fresenius Kabi Austria
GmbH, Graz, Austria), which was diluted into 4% solution with
LR for intravenous infusion because Ala-Gln must be diluted
five times for intravenous administration in clinical application.
Five to seven milliliters of 4% Ala-Gln was administered to
yield 0.75 g/kg per dose of Gln. Ala-Gln solution or LR vehicle
was administered via femoral vein injection.
Measurement of mean arterial pressure
All rats were anesthetized with sodium pentobarbital (40 mg/
kg intraperitoneally), and a supplemental dose (20 mg/kg) was
added if necessary. The rats were allowed to keep breathing
spontaneously. One catheter was placed in the femoral artery
and connected to the pressure transducers for recording
mean arterial pressure (MAP), and another one was placed in
the femoral vein as a route for drug administration. MAP values
of the rats were decreased after administration of LPS in the
LPS group and the Ala-Gln+LPS group, and an MAP
decrease of 25% to 30% of baseline level was regarded as
endotoxin shock [15]. Six hours after administration of LPS,
phenylephrine (PE) (Shanghai Harvest Pharmaceutical Co.,
Ltd., Shanghai, China) in doses of 0.5, 1.0, 2.0, and 2.5 μg/kg
was applied every 20 minutes via the femoral vein; the per-
centage increase in MAP was recorded in each group.
Isolated vascular function
All rats were anesthetized by sodium pentobarbital and killed
by decapitation after levels of MAP were measured. The tho-
racic aorta was rapidly isolated and prepared with the
endothelium intact. Vascular segments (3 to 4 mm) were sus-
pended by stainless steel hooks in 10-ml tissue baths contain-
ing Krebs buffer at 37°C, oxygenated by constant bubbling of
a 95%/5% O2/CO2 mixture, and incubated for 90 minutes.
Tension data were collected with the Biologic Signal Collect-
ing System (Nanjing Medical University, Nanjing, China). After
five washes, concentration effect data were obtained by
cumulative addition of PE (1 × 10-9 to 1 × 10-4 M; Sigma-
Aldrich).
HSP70 protein expression detection with Western 
blotting analysis
Six hours after injection of LPS, the heart, liver, lung, and aorta
were harvested, immediately frozen in liquid nitrogen, and
stored at -80°C until analysis. Tissues were homogenized in
buffer (10 mM Tris, 5 mM EDTA [ethylenediaminetetraacetic
acid], 2% Triton X-100, 0.2 mM Na3VO4, 1 mM phenylmethyl-
sulfonyl fluoride, and 10 μg/ml leupeptin and aprotinin) and
mechanically disrupted. Samples were analyzed by SDS-
PAGE by means of a transfer buffer (25 mM/l Tris, 192 mM/l
glycine, and 20% methanol) in a wet-transfer apparatus. Blots
were blocked with 5% non-fat dry milk in phosphate-buffered
saline with 0.1% Tweens-20 and then incubated with mouse
anti-rat monoclonal HSP70 antibody (Sigma-Aldrich). After
repeated washing, rabbit anti-mouse secondary antibody
(horseradish peroxidase-conjugated) incubation was per-
formed, developed with a chemiluminescence system, and fol-
lowed with film exposure and relative intensity analysis.
Detection of plasma tumor necrosis factor-alpha, 
interleukin-6, and malondialdehyde
The arterial blood sample (1.5 ml) was collected from all
groups at 90 minutes (for tumor necrosis factor-alpha [TNF-α]
detection, plasma peak was thought to be achieved within twoAvailable online http://ccforum.com/content/11/2/R34
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hours after LPS injection [16]) and six hours (for plasma inter-
leukin-6 [IL-6] and malondialdehyde [MDA] detection) after
administration of LPS. Blood was then centrifuged for eight
minutes at 3,500 g and 4°C, and the supernatant was col-
lected. The plasma IL-6 and TNF-α were analyzed using
enzyme-linked immunosorbent assay kits (Shanghai Hua Sen
Science & Technology CO. Ltd., Shanghai, China). Results
were then obtained using a microplate reader (Model 680;
Bio-Rad Laboratories, Inc, Tokyo, Japan). The content of
plasma MDA levels was measured by means of a thibabituric
acid reaction.
Statistical analysis
Concentration-response data were fitted to a sigmoidal maxi-
mum efficacy (Emax) model by means of GraphPad Prism soft-
ware (GraphPad Software, Inc., San Diego, CA, USA). The
values of PE Emax and median effective dose (EC50) were
determined for each treatment group. Data are presented as
mean ± standard deviation. Statistical analyses were per-
formed using one-way analyses of variance. All analysis was
performed using the Statistical Software Package (SPSS ver-
sion 11.5; SPSS Inc., Chicago, IL, USA). Statistical signifi-
cance was assigned at a P value of less than 0.05.
Results
Changes in mean arterial pressure in response to 
phenylephrine
There were no significant differences in baseline levels of MAP
among the groups, but MAP decreased to 75% to 70% of the
baseline level six hours after administration of LPS. PE pro-
duced a dose-dependent increase in MAP in all groups, but
the maximal percentage increase in MAP significantly
decreased to 12.7% in the LPS shock group (P < 0.05) and
was restored to 15.6% in the Ala-Gln+LPS group whereas the
maximal percentage increase in the control group was 24.7%
(P < 0.05) (Figure 1).
Isolated vascular response to phenylephrine
In the vascular tension experiments, each tissue developed
tension to PE in a concentration-dependent way. The average
values of PE EC50 and Emax in the control group were 8.55 ±
0.08 nmol/l and 1.86 ± 0.05 g, respectively (Table 1). PE Emax
significantly decreased to 51% (0.95 ± 0.01 g) in the LPS
shock group and was restored to 68% (1.27 ± 0.03 g) in the
Ala-Gln+LPS group, whereas PE Emax in the control group was
taken as 100% (P < 0.05) (Figure 2, Table 1). Likewise, fitted
PE EC50 significantly increased to 13.49 ± 0.06 nmol/l in the
LPS shock group and was reversed to 10.15 ± 0.04 nmol/l in
the Ala-Gln+LPS group (P < 0.05) (Table 1).
Glutamine enhances HSP70 expression
The analyses from Western blotting showed that HSP70
expressions in heart tissue (Figure 3a), aorta tissue (Figure
3b), lung tissue (Figure 3c), and liver tissue (Figure 3d) were
weak in the control group but markedly stronger in the LPS
shock group (P < 0.05). The expressions of HSP70 were
much higher than those in the LPS shock group from four tis-
sues in the Ala-Gln+LPS group (P < 0.05) (Figure 3a–d).
Figure 1
The percentage increase in mean arterial pressure (MAP) induced by  phenylephrine in different groups of rats The percentage increase in mean arterial pressure (MAP) induced by 
phenylephrine in different groups of rats. The maximal percentage 
increase in MAP significantly decreased to 12.7% in the LPS shock 
group (P < 0.05) and was restored to 15.6% in the Ala-Gln+LPS 
group, whereas the maximum percentage increase in the control group 
was 24.7% (n = 8, mean ± standard deviation). *P < 0.05 versus the 
Ala-Gln+LPS group; #P < 0.05 versus the control group. Ala-Gln+LPS, 
alanyl-glutamine dipeptide + lipopolysaccharide shock; LPS shock, 
lipopolysaccharide shock.
Table 1
The values of PE Emax and EC50 on aortic rings in the different groups of rats
Group Emax (g) EC50 (nmol/l)
Control 1.86 ± 0.04 8.55 ± 0.08
LPS shock 0.95 ± 0.01a 13.49 ± 0.06a
Ala-Gln+LPS 1.27 ± 0.02a,b 10.15 ± 0.04a,b
Data are shown as mean ± standard deviation (n = 8 in each group). aP < 0.05 versus the control group; bP < 0.05 versus the LPS shock group. 
Ala-Gln+LPS, alanyl-glutamine dipeptide + lipopolysaccharide shock; Emax, maximum efficacy; EC50, median effective dose; LPS, 
lipopolysaccharide.Critical Care    Vol 11 No 2    Jing et al.
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Glutamine decreases plasma concentrations of TNF-α, 
IL-6, and MDA
The plasma TNF-α, IL-6, and MDA levels were low in the con-
trol group (49.7 ± 12.2 pg/ml, 23.5 ± 9.2 pg/ml, and 4.66 ±
0.55 mol/ml, respectively). They significantly increased in the
LPS shock group (293.1 ± 52.2 pg/ml, 296.2 ± 60.2 pg/ml,
and 9.71 ± 0.87 mol/ml, respectively; P < 0.01) (Table 2). Pre-
treatment with Ala-Gln significantly decreased plasma con-
centrations of TNF-α, IL-6, and MDA compared with the LPS
shock group (131.8 ± 27.7 pg/ml, 204.1 ± 42.2 pg/ml, and
5.89 ± 0.58 mol/ml, respectively; P < 0.05) (Table 2).
Discussion
The results of this study demonstrate that pretreatment of Ala-
Gln significantly improved vascular response to catecho-
lamine vasoconstrictors and that the effect of Ala-Gln is asso-
ciated with its capacity to induce HSP70 expression and
attenuate release of pro-inflammatory cytokines and oxidizing
species production after septic shock. HSP70 is the most
important protein in HSP family to generate a protective effect
against injuries in the presence of various stresses [17]. Previ-
ous studies in rat models of HSP induction to protect against
septic shock have used sodium arsenite or heat as an inducer
for the stress response. Sodium arsenite is known to be quite
toxic; a previous experiment showed a 20% mortality rate from
the arsenite alone [18]. HSP expression has also been
induced by measures that increase core body temperature
[19]. However, these measures are clinically impractical
because they would be poorly tolerated by patients and would
have detrimental effects on many cellular functions [20]. Gln
may have therapeutic value in safely and effectively enhancing
the expression of HSP and may increase the survival from sep-
tic shock [21]. Therefore, we chose Ala-Gln as an HSP
expression inducer in this study.
In the present study, we designed pretreatment of 0.75 g/kg
Gln to be one hour before LPS injection and performed a vas-
cular functional test six hours after administration of LPS. The
dose of Gln dipeptide used in this study was based on our pre-
vious data, which indicate that the maximal HSP70 mRNA
expression in rats occurs at 6 to approximately 12 hours after
an intravenous dose of 0.75 g/kg Gln. This dose has also been
demonstrated to safely induce HSP70 expression in sepsis
rats [22]. One limitation of this study seems to be that we
chose the pretreatment of Ala-Gln rather than to treat at the
onset or after a septic injury since the latter is more likely to get
close to the clinical utility. This was done because from our
previous experimental data, we know that the maximal HSP70
expression occurs at six hours after Ala-Gln is used. However,
administration of LPS results in hypotension at the third to
fourth hour in rats [23]. If Gln injection time is same with or
post LPS application, maybe could not exactly evaluate the
protective effect of Gln on vascular reactivity because Gln-
induced maximal HSP expression dose not obtained.
A potential limitation of this study is that we chose to use a
vehicle-based control rather than an iso-nitrogenous amino
acid control. Previous studies have shown that alanine does
not lead to significant enhancement of HSP70 either in ani-
mals [24] or patients [25], suggesting that the pharmacologi-
cal effects we have observed are related to the Gln treatment.
Ala-Gln must be diluted five times for intravenous administra-
tion based on its description; therefore, there is an excessive
amount of fluid infusion in the present study. This acute volume
overloading results in slight increases in blood pressure and
heart rate but does not lead to death in rats. The effects of vol-
ume overloading on the measurement of MAP should be con-
sidered. However, the volume of infusion in every
administration was strictly controlled according to body
weight to be the same in the three groups, and the MAP still
decreased after administration of LPS. This indicates that,
although volume overloading could temporarily change the
hemodynamics in rats, the change of MAP could still be con-
sidered a sensitive parameter that reflected vascular response
to agonists in the present study. Furthermore, a total of 3 ml of
blood was drawn at 90 minutes and 6 hours before the start
of the experiment and this may have partially reduced the influ-
ence of hypervolemia.
Endotoxin shock is characterized by a marked oxidant stress
[26] and a rapid production of different cytokines [27].
Nuclear factor-kappa-B is a transcription factor that plays a
central role in the modulation of the inflammatory and immune
responses and induces the expression of many genes of
inducible nitric oxide synthase, cytokine tissue factor, and
Figure 2
The concentration-response curves of phenylephrine (PE) in aortic  rings from different groups of rats (mean ± standard deviation) The concentration-response curves of phenylephrine (PE) in aortic 
rings from different groups of rats (mean ± standard deviation). PE max-
imum efficacy (Emax) significantly decreased to 51% in the LPS shock 
group and was restored to 68% in the Ala-Gln+LPS group (P < 0.05), 
whereas PE Emax in the control group was taken as 100%. *P < 0.05 
versus the Ala-Gln+LPS group. #P < 0.05 versus the control group. 
Ala-Gln+LPS, alanyl-glutamine dipeptide + lipopolysaccharide shock; 
LPS shock, lipopolysaccharide shock.Available online http://ccforum.com/content/11/2/R34
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adhesion molecules involved in the pathogenesis of endotoxin
shock [28]. The results of our study showed that the levels of
plasma TNF-α, IL-6, and MDA in the Ala-Gln+LPS group were
lower than those in the LPS shock group, indicating that the
inhibited pro-inflammatory cytokine release and peroxide pro-
duction may also be attributed to the protective effects of Gln
on LPS-induced vascular hyporeactivity. The mechanism
involved may be that Gln inhibits the expression of the inflam-
matory cytokines directly [22] or that Gln-induced HSP70
expression further enhanced this effect [29].
The data provided in this study demonstrate two discrete
mechanistic effects produced by Ala-Gln, namely the reduced
LPS-induced cytokine presence in plasma and the increased
HSP70 in multiple tissues. The actual upstream mechanisms
responsible for these changes are not clear, but they may be
separately regulated and influenced by Ala-Gln. We
hypothesize that this dual effect of decreased cytokine-
induced vascular injury/action and increased vascular cell sur-
vival may be critical for the improved outcomes we observed.
Further studies to define the molecular pathways responsible
for these discrete actions are clearly warranted, as is further
investigation of Gln as a modulator of sepsis-related cardio-
vascular outcomes.
Figure 3
Effects of alanyl-glutamine on heat-shock protein 70 (HSP70) expression in heart, aorta, lung, and liver in endotoxin rats Effects of alanyl-glutamine on heat-shock protein 70 (HSP70) expression in heart, aorta, lung, and liver in endotoxin rats. HSP70 expressions were 
analyzed by Western blotting analysis. Relative density refers to the ratio of HSP70 to GAPDH. The expression of HSP70 was significantly 
increased after lipopolysaccharide (LPS) injection compared with the control group in heart (a), aorta (b), lung (c), and liver (d) tissue. (*P < 0.05; n 
= 5). The expressions of HSP70 were much higher than those in the LPS shock group from four tissues in the Ala-Gln+LPS group (#P < 0.05; n = 
5). Ala-Gln+LPS, alanyl-glutamine dipeptide + lipopolysaccharide shock; Ala+LPS, alanyl-glutamine dipeptide + lipopolysaccharide shock; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; LPS+Gln, alanyl-glutamine dipeptide + lipopolysaccharide shock.Critical Care    Vol 11 No 2    Jing et al.
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Conclusion
Gln has been well demonstrated to protect against organ dys-
function in animal experiments and in critically ill patients by
inducing HSP70 expression, attenuating sepsis-induced met-
abolic dysfunction, and reducing inflammatory cytokine
release and peroxide production. Here, we further demon-
strated that administration of a dose of 0.75 g/kg Gln could
protect against vascular hyporeactivity in endotoxic shock rats.
Thus, Ala-Gln could be used to induce the protective stress
response and prevent end-organ injury and possibly decrease
mortality from sepsis and improve outcomes in critically ill
patients.
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